These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 15462490

  • 1. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus.
    Tam LS, Li EK, Wong CK, Lam CW, Szeto CC.
    Lupus; 2004; 13(8):601-4. PubMed ID: 15462490
    [Abstract] [Full Text] [Related]

  • 2. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study.
    Remer CF, Weisman MH, Wallace DJ.
    Lupus; 2001; 10(7):480-3. PubMed ID: 11480845
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
    [Abstract] [Full Text] [Related]

  • 4. Analysis of changes in joint function and peripheral blood mononuclear cells in patients with systemic lupus erythematosus and intervention effects of different drugs.
    Zhou QS, Hu J, Hu H.
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4423-4430. PubMed ID: 29077150
    [Abstract] [Full Text] [Related]

  • 5. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial.
    Chang DM, Lan JL, Lin HY, Luo SF.
    Arthritis Rheum; 2002 Nov; 46(11):2924-7. PubMed ID: 12428233
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in patients with systemic lupus erythematosus.
    Bengtsson AA, Sturfelt G, Lood C, Rönnblom L, van Vollenhoven RF, Axelsson B, Sparre B, Tuvesson H, Ohman MW, Leanderson T.
    Arthritis Rheum; 2012 May; 64(5):1579-88. PubMed ID: 22131101
    [Abstract] [Full Text] [Related]

  • 7. Tibolone in postmenopausal women with systemic lupus erythematosus: a pilot study.
    Vieira CS, Pereira FV, de Sá MF, Paulo LJ, Martins WP, Ferriani RA.
    Maturitas; 2009 Mar 20; 62(3):311-6. PubMed ID: 19193505
    [Abstract] [Full Text] [Related]

  • 8. Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial.
    Mok CC, Ying SK, Ma KM, Wong CK.
    Lupus; 2013 Dec 20; 22(14):1470-8. PubMed ID: 24113197
    [Abstract] [Full Text] [Related]

  • 9. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.
    Cheng LE, Amoura Z, Cheah B, Hiepe F, Sullivan BA, Zhou L, Arnold GE, Tsuji WH, Merrill JT, Chung JB.
    Arthritis Rheumatol; 2018 Jul 20; 70(7):1071-1076. PubMed ID: 29513931
    [Abstract] [Full Text] [Related]

  • 10. Leflunomide: friend or foe for systemic lupus erythematosus?
    Wu GC, Xu XD, Huang Q, Wu H.
    Rheumatol Int; 2013 Feb 20; 33(2):273-6. PubMed ID: 22961090
    [Abstract] [Full Text] [Related]

  • 11. Open label randomized controlled trial assessing the efficacy of mycophenolate sodium against other conventional immunosuppressive agents in active systemic lupus erythematosus patients without renal involvement.
    Yahya F, Jasmin R, Ng CT, Cheah TE, Sockalingam S.
    Int J Rheum Dis; 2013 Dec 20; 16(6):724-30. PubMed ID: 24119227
    [Abstract] [Full Text] [Related]

  • 12. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.
    Petri MA, Lahita RG, Van Vollenhoven RF, Merrill JT, Schiff M, Ginzler EM, Strand V, Kunz A, Gorelick KJ, Schwartz KE, GL601 Study Group.
    Arthritis Rheum; 2002 Jul 20; 46(7):1820-9. PubMed ID: 12124866
    [Abstract] [Full Text] [Related]

  • 13. Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study.
    Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, Sosa-Muñoz J, Miranda JM, Jara LJ.
    Lupus; 1998 Jul 20; 7(6):414-9. PubMed ID: 9736326
    [Abstract] [Full Text] [Related]

  • 14. [Leflunomide in systemic lupus erythematosus].
    Kessel A, Toubi E.
    Harefuah; 2002 Apr 20; 141(4):355-7, 409. PubMed ID: 12017890
    [Abstract] [Full Text] [Related]

  • 15. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, Marder G, Rosenthal P, Haines K, Ilie V, Abramson SB.
    Arthritis Rheum; 2006 Nov 20; 54(11):3623-32. PubMed ID: 17075807
    [Abstract] [Full Text] [Related]

  • 16. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
    Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE.
    Arthritis Rheum; 2004 Sep 20; 50(9):2858-68. PubMed ID: 15452837
    [Abstract] [Full Text] [Related]

  • 17. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus.
    Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, Bengtsson AA, Reich A, de Vries DE, van Hartingsveldt B, Robinson DW, Gordon R, Hsu B.
    Arthritis Rheum; 2013 Oct 20; 65(10):2661-71. PubMed ID: 23896980
    [Abstract] [Full Text] [Related]

  • 18. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
    Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D, IDEC-131 Lupus Study Group.
    Arthritis Rheum; 2002 Dec 20; 46(12):3251-8. PubMed ID: 12483729
    [Abstract] [Full Text] [Related]

  • 19. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
    Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA, PEARL-SC Study.
    Ann Rheum Dis; 2015 Sep 20; 74(9):1667-75. PubMed ID: 24748629
    [Abstract] [Full Text] [Related]

  • 20. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA, LBSL02/99 Study Group.
    J Rheumatol; 2014 Feb 20; 41(2):300-9. PubMed ID: 24187095
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.